Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?

Key Takeaways Intellia has completed enrollment in phase III HAELO study for lonvo-z in hereditary angioedema.The company expects to file a biologics license application for lonvo-z in the second half of 2026.Nex-z, developed with Regeneron, is in two phase III studies for ATTR amyloidosis indications.Intellia Therapeutics (NTLA) has made meaningful progress with the development of its in vivo programs. The company is currently advancing two late-stage in vivo candidates — lonvo-z (or, NTLA-2002) for heredi ...